Manufactured for Immuno-Biological Laboratories Inc. (IBL-America) 8201 Central Avenue, NE, Suite P Minneapolis, MN 55432 Tel: 763-780-2955 Toll Free: 1-888-523-1246




Instructions for use **3-CAT RIA**

¹²⁵I – Radioimmunoassay for the quantitative determination of Adrenaline (Epinephrine), Noradrenaline (Norepinephrine) and Dopamine in plasma and urine.

For *in-vitro* diagnostic use only.











1.1 Intended use and principle of the test

¹²⁵I – Radioimmunoassay for the quantitative determination of Adrenaline (Epinephrine), Noradrenaline (Norepinephrine) and Dopamine in plasma and urine. For *in-vitro* diagnostic use only.

Adrenaline (epinephrine), noradrenaline (norepinephrine) and dopamine are extracted by using a cis-diol-specific affinity gel, acylated and then converted enzymatically.

The assay procedure follows the basic principle of radioimmunoassay, involving competition between a radioactive and a non-radioactive antigen for a fixed number of antibody binding sites. The amount of ¹²⁵I-labelled antigen bound to the antibody is inversely proportional to the analyte concentration of the sample. When the system is in equilibrium, the antibody bound radioactivity is precipitated with a second antibody in the presence of polyethylene glycol. The precipitate is counted in a gamma counter. Quantification of unknown samples is achieved by comparing their activity with a standard curve prepared with known standards.

1.2 Clinical application

In humans the catecholamines adrenaline (epinephrine), noradrenaline (norepinephrine) and dopamine are neurotransmitters of the sympathetic nervous system and are involved in many physiological processes. The sympathetic nervous system sets the body to a heightened state of alert, also called as the body's fight-or-flight response.

In the human body the catecholamines and their metabolites indicate the adaption of the body to acute and chronic stress.

Next to the metanephrine/normetanephrine the catecholamines are important for the diagnosis and the follow-up of tumors of the sympathoadrenal system like the pheochromocytoma. The quantitative determination of catecholamines in urine is preferred for the diagnosis of these tumors, whereas the determination of catecholamines in plasma is medically sensible for the localization of the tumor and for function testing. Values above the cut-off can provide an indication for neuroendocrine tumors.

However, in literature various diseases like hypertension, cardiovascular diseases, schizophrenia and manic depression are described with different levels of catecholamines.

Therapeutic consequences should never be based on laboratory results alone even if all test results are in agreement with the items as under point "Procedural cautions, guidelines and warnings". Any laboratory result is only a part of the total clinical picture of the patient.

Only in cases where the laboratory results are in an acceptable agreement with the overall clinical picture of the patient it can be used for therapeutic consequences.

The test result itself should never be the sole determinant for deriving any therapeutic consequences.

2. <u>Procedural cautions, guidelines, warnings and limitations</u>

2.1 Precautions, guidelines and warnings

- (1) This kit is intended for professional use only. Users should have a thorough understanding of this protocol for the successful use of this kit. Only the test instruction provided with the kit is valid and has to be used to run the assay. Reliable performance will only be attained by strict and careful adherence to the instructions provided.
- (2) This assay was validated for certain types of sample as indicated in *Intended Use* (please refer to Chapter 1). Any off-label use of this kit is in the responsibility of the user and the manufacturer cannot be held liable.
- (3) The principles of Good Laboratory Practice (GLP) have to be followed.
- (4) In order to reduce exposure to potentially harmful substances, wear lab coats, disposable protective gloves and protective glasses where necessary.
- (5) All kit reagents with the exception of Precipitating Reagent and specimens should be brought to room temperature and mixed gently but thoroughly before use. Avoid repeated freezing and thawing of reagents and specimens.
- (6) For the dilution or reconstitution purposes use deionized, distilled, or ultra-pure water.
- (7) The radioactive material (¹²⁵Iodine, half life 60 days, emitting ionizing X-radiation with 28 keV and G-radiation with 35.5 keV) may be received, acquired, possessed and used only by physicians, laboratories or hospitals. In compliance with regulations, a copy of the customer's current radioisotope license must be on file with the supplier. Orders cannot be shipped until the license is received by the supplier (Radiation Protection Act of June 30, 1989).
- (8) Duplicate determination of sample is highly recommended to be able to identify potential pipetting errors.
- (9) Once the test has been started, all steps should be completed without interruption. Make sure that the required reagents, materials and devices are prepared ready at the appropriate time.
- (10) Incubation times do influence the results. All tubes should be handled in the same order and time intervals.
- (11) To avoid cross-contamination of reagents, use new disposable pipette tips for dispensing each reagent, sample, standard and control.

English

- (12) A standard curve must be established for each run.
- (13) The controls should be included in each run and fall within established confidence limits. The confidence limits are listed in the QC-Report provided with the kit.
- (14) Do not mix kit components with different lot numbers within a test and do not use reagents beyond expiry date as shown on the kit labels.
- (15) For information on hazardous substances included in the kit please refer to Material Safety Data Sheets (MSDS). The Material Safety Data Sheet for this product is available directly on the website of the manufacturer or upon request.
- (16) The expected reference values reported in this test instruction are only indicative. It is recommended that each laboratory establishes its own reference intervals.
- (17) The results obtained with this test kit should not be taken as the sole reason for any therapeutic consequence (e.g. medication before a scheduled surgery) but have to be correlated to other diagnostic tests and clinical observations.
- (18) Kit reagents must be regarded as hazardous waste and disposed of according to national regulations.

2.2 Limitations

Any inappropriate handling of samples or modification of this test might influence the results.

2.2.1 Interfering substances

Plasma

Samples containing precipitates or fibrin strands or which are haemolytic or lipemic might cause inaccurate results.

24-hour urine

Please note the sample preparation! If the percentage of the final concentration of acid is too high, the buffer capacity of the Extraction Buffer is insufficient. As a consequence catecholamines will not be extracted adequately.

2.2.2 Drug interferences

There are no known substances (drugs) which ingestion interferes with the measurement of catecholamine level in the sample.

2.2.3 High-Dose-Hook effect

No hook effect was observed in this test.

3. Storage and stability

Store the unopened reagents at 2 - 8 °C until expiration date. Do not use components beyond the expiry date indicated on the kit labels. Once opened the reagents are stable for 1 month when stored at 2 - 8 °C.

4. <u>Materials</u>

4.1 Content of the kit

BA D-0090	FOILS	Adhesive Foil - Ready to use
Content:	Adhesive Foils in	a resealable pouch
Volume:	1 x 4 foils	

BA R-0025	PREC-REAG	Precipitating Reagent - Ready to use
Content:	Goat anti-rabbit	serum in PEG phosphate buffer
Volume:	3 x 55 ml/vial, v	vhite cap
BA R-6618	EXTRACT-PLATE 48	Extraction Plate - Ready to use
Content:	2 x 48 well plate	es coated with boronate affinity gel in a resealable pouch
BA R-0050	ADJUST-BUFF	Adjustment Buffer - Ready to use
Content:	TRIS buffer	
Volume:	2 x 4 ml/vial, gr	een cap
BA R-0120	¹²⁵ I ADR MN	125I – Adrenaline - Ready to use
Content:	¹²⁵ I labeled Adre	enaline, red coloured
Volume:	1 x 5.5 ml/vial,	blue cap
Hazards identification:	*	

Effective: 2015-07-06

3/11

BA R-0220	¹²⁵ I NAD NMN	125I – Noradrenaline - Ready to use
Content:		drenaline, red coloured
Volume:	1 x 5.5 ml/vial, y	ellow cap
Hazards identification:	*	
	Radioactive, activ	/ity < 200 kBq
BA R-0320	¹²⁵ I DOP	125I – Dopamine - Ready to use
Content:	¹²⁵ I labeled Dopa	mine, red coloured
Volume:	1 x 5.5 ml/vial, d	ark green cap
Hazards identification:	*	
	Radioactive, activ	/ity < 200 kBq
BA R-6110	AS ADR MN	Adrenaline Antiserum - Ready to use
Content:	Rabbit anti- Adre	naline antibody, blue coloured
Volume:	1 x 5.25 ml/vial,	blue cap
BA R-6210	AS NAD	Noradrenaline Antiserum - Ready to use
Content:		drenaline antibody, yellow coloured
Volume:	1 x 5.25 ml/vial,	yellow cap
BA R-6310	AS DOP	Dopamine Antiserum - Ready to use
Content:	Rabbit anti- Dopa	mine antibody, green coloured
Volume:	1 x 5.25 ml/vial,	dark green cap
BA R-6611	ACYL-BUFF	Acylation Buffer - Ready to use
Content:	Buffer with light a	alkaline pH
		alkaline pH
Content: Volume: BA R-6612	Buffer with light a 1 x 20 ml/vial, w	alkaline pH hite cap Acylation Reagent - Ready to use
Content: Volume: BA R-6612 Content:	Buffer with light a 1 x 20 ml/vial, w ACYL-REAG Acylation reagent	alkaline pH hite cap Acylation Reagent - Ready to use t in DMF and DMSO
Content: Volume: BA R-6612 Content: Volume:	Buffer with light a 1 x 20 ml/vial, w	alkaline pH hite cap Acylation Reagent - Ready to use t in DMF and DMSO
Content: Volume: BA R-6612 Content:	Buffer with light a 1 x 20 ml/vial, w ACYL-REAG Acylation reagent	alkaline pH hite cap Acylation Reagent - Ready to use t in DMF and DMSO
Content: Volume: BA R-6612 Content: Volume: Hazards	Buffer with light a 1 x 20 ml/vial, w ACYL-REAG Acylation reagent 1 x 3 ml/vial, light Weight Constraints H225 Highly flamt H360 May damage	alkaline pH hite cap Acylation Reagent - Ready to use t in DMF and DMSO
Content: Volume: BA R-6612 Content: Volume: Hazards	Buffer with light a 1 x 20 ml/vial, w ACYL-REAG Acylation reagent 1 x 3 ml/vial, light Weight Constraints H225 Highly flamt H360 May damage	Alkaline pH hite cap Acylation Reagent - Ready to use t in DMF and DMSO nt red cap mable liquid and vapour. ge fertility or the unborn child.
Content: Volume: BA R-6612 Content: Volume: Hazards identification:	Buffer with light a 1 x 20 ml/vial, w Acylation reagent 1 x 3 ml/vial, light 1 x 3 ml/vial, light 4225 Highly flam H360 May damag H319 Causes seri ASSAY-BUFF 1M hydrochloric a	Acylation Reagent - Ready to use Acylation Reagent - Ready to use t in DMF and DMSO at red cap mable liquid and vapour. ye fertility or the unborn child. ious eye irritation. Assay Buffer - Ready to use acid and a non-mercury preservative
Content: Volume: BA R-6612 Content: Volume: Hazards identification: BA R-6613	Buffer with light a 1 x 20 ml/vial, w ACYL-REAG Acylation reagent 1 x 3 ml/vial, ligh With the second	Acylation Reagent - Ready to use Acylation Reagent - Ready to use t in DMF and DMSO at red cap mable liquid and vapour. ye fertility or the unborn child. ious eye irritation. Assay Buffer - Ready to use acid and a non-mercury preservative
Content: Volume: BA R-6612 Content: Volume: Hazards identification: BA R-6613 Content:	Buffer with light a 1 x 20 ml/vial, w ACYL-REAG Acylation reagent 1 x 3 ml/vial, ligh With the second second H225 Highly flam H360 May damag H319 Causes second ASSAY-BUFF 1M hydrochloric a 1 x 6 ml/vial, light COENZYME	Acylation Reagent - Ready to use Acylation Reagent - Ready to use t in DMF and DMSO int red cap mable liquid and vapour. the fertility or the unborn child. ious eye irritation. Assay Buffer - Ready to use acid and a non-mercury preservative at grey cap Coenzyme - Ready to use
Content: Volume: BA R-6612 Content: Volume: Hazards identification: BA R-6613 Content: Volume: BA R-6614 Content:	Buffer with light a 1 x 20 ml/vial, w Acylation reagent 1 x 3 ml/vial, light Acylation reagent 1 x 3 ml/vial, light H225 Highly flam H360 May damag H319 Causes series ASSAY-BUFF 1M hydrochloric a 1 x 6 ml/vial, light COENZYME S-adenosyl-L-me	Acylation Reagent - Ready to use Acylation Reagent - Ready to use t in DMF and DMSO at red cap mable liquid and vapour. Je fertility or the unborn child. Jous eye irritation. Assay Buffer - Ready to use acid and a non-mercury preservative at grey cap Coenzyme - Ready to use thionine
Content: Volume: BA R-6612 Content: Volume: Hazards identification: BA R-6613 Content: Volume: BA R-6614	Buffer with light a 1 x 20 ml/vial, w ACYL-REAG Acylation reagent 1 x 3 ml/vial, ligh With the second second H225 Highly flam H360 May damag H319 Causes second ASSAY-BUFF 1M hydrochloric a 1 x 6 ml/vial, light COENZYME	Acylation Reagent - Ready to use Acylation Reagent - Ready to use t in DMF and DMSO at red cap mable liquid and vapour. Je fertility or the unborn child. Jous eye irritation. Assay Buffer - Ready to use acid and a non-mercury preservative at grey cap Coenzyme - Ready to use thionine
Content: Volume: BA R-6612 Content: Volume: Hazards identification: BA R-6613 Content: Volume: BA R-6614 Content: Volume: BA R-6615	Buffer with light a 1 x 20 ml/vial, w Acylation reagent 1 x 3 ml/vial, light Acylation reagent H225 Highly flam H360 May damag H319 Causes series ASSAY-BUFF 1M hydrochloric a 1 x 6 ml/vial, light COENZYME S-adenosyl-L-me 1 x 4 ml/vial, pur ENZYME	Acylation Reagent - Ready to use a cylation Reagent - Ready to use a in DMF and DMSO at red cap mable liquid and vapour. be fertility or the unborn child. a cous eye irritation. Assay Buffer - Ready to use acid and a non-mercury preservative at grey cap Coenzyme - Ready to use thionine ple cap Enzyme - Lyophilized
Content: Volume: BA R-6612 Content: Volume: Hazards identification: BA R-6613 Content: Volume: BA R-6614 Content: Volume: BA R-6615 Content:	Buffer with light a 1 x 20 ml/vial, w ACYL-REAG Acylation reagent 1 x 3 ml/vial, ligh With the second second H225 Highly flam H360 May damag H319 Causes series ASSAY-BUFF 1M hydrochloric a 1 x 6 ml/vial, light COENZYME S-adenosyl-L-me 1 x 4 ml/vial, pur ENZYME Catechol-O-meth	Acylation Reagent - Ready to use a cylation Reagent - Ready to use a in DMF and DMSO at red cap mable liquid and vapour. be fertility or the unborn child. a cous eye irritation. Assay Buffer - Ready to use acid and a non-mercury preservative at grey cap Coenzyme - Ready to use thionine ple cap Enzyme - Lyophilized
Content: Volume: BA R-6612 Content: Volume: Hazards identification: BA R-6613 Content: Volume: BA R-6614 Content: Volume: BA R-6615 Content: Volume:	Buffer with light a 1 x 20 ml/vial, w ACYL-REAG Acylation reagent 1 x 3 ml/vial, ligh With a ml/vial, ligh H225 Highly flam H360 May damag H319 Causes series ASSAY-BUFF 1M hydrochloric a 1 x 6 ml/vial, ligh COENZYME S-adenosyl-L-me 1 x 4 ml/vial, pur ENZYME Catechol-O-meth 6 vials, pink cap	Acylation Reagent - Ready to use in DMF and DMSO at red cap mable liquid and vapour. be fertility or the unborn child. bous eye irritation. Assay Buffer - Ready to use acid and a non-mercury preservative at grey cap Coenzyme - Ready to use thionine ple cap Enzyme - Lyophilized yltransferase
Content: Volume: BA R-6612 Content: Volume: Hazards identification: BA R-6613 Content: Volume: BA R-6614 Content: Volume: BA R-6615 Content: Volume: BA R-6615	Buffer with light a 1 x 20 ml/vial, w Acylation reagent 1 x 3 ml/vial, light Acylation reagent H225 Highly flam H360 May damag H319 Causes series Assay-BUFF 1M hydrochloric a 1 x 6 ml/vial, light CoENZYME S-adenosyl-L-me 1 x 4 ml/vial, pur ENZYME Catechol-O-meth 6 vials, pink cap EXTRACT-BUFF	Acylation Reagent - Ready to use t in DMF and DMSO at red cap mable liquid and vapour. te fertility or the unborn child. tous eye irritation. Assay Buffer - Ready to use acid and a non-mercury preservative at grey cap Coenzyme - Ready to use thionine rple cap Enzyme - Lyophilized yltransferase Extraction Buffer - Ready to use
Content: Volume: BA R-6612 Content: Volume: Hazards identification: BA R-6613 Content: Volume: BA R-6614 Content: Volume: BA R-6615 Content: Volume:	Buffer with light a 1 x 20 ml/vial, w ACYL-REAG Acylation reagent 1 x 3 ml/vial, ligh With a ml/vial, ligh H225 Highly flam H360 May damag H319 Causes series ASSAY-BUFF 1M hydrochloric a 1 x 6 ml/vial, ligh COENZYME S-adenosyl-L-me 1 x 4 ml/vial, pur ENZYME Catechol-O-meth 6 vials, pink cap	Acylation Reagent - Ready to use a cylation Reagent - Ready to use a in DMF and DMSO at red cap mable liquid and vapour. Je fertility or the unborn child. ious eye irritation. Assay Buffer - Ready to use acid and a non-mercury preservative at grey cap Coenzyme - Ready to use thionine rple cap Enzyme - Lyophilized yltransferase Extraction Buffer - Ready to use carbonate

BA R-6619	HCL	Hydrochloric Acid - Ready to use
-----------	-----	----------------------------------

Content: 0.025 M Hydrochloric Acid, yellow coloured

Volume: 1 x 20 ml/vial, dark green cap

Standards and Controls - Ready to use

Cat. no.	Component	Colour/ Cap	Concen ADR	NAD	ng/ml DOP	Concen ADR	tration NAD	nmol/l DOP	Volume/ Vial
BA R-6601	STANDARD A	white	0	0	0	0	0	0	4 ml
BA R-6602		light yellow	1	5	10	5.5	30	65	4 ml
		light yellow		-	-				
BA R-6603	STANDARD C	orange	4	20	40	22	118	261	4 ml
BA R-6604	STANDARD D	dark blue	15	75	150	82	443	980	4 ml
BA R-6605	STANDARD E	light grey	50	250	500	273	1 478	3 265	4 ml
BA R-6606	STANDARD F	black	200	1 000	2 000	1 092	5 910	13 060	4 ml
BA R-6609	STANDARD A/B	light purple	-	-	4.5	-	-	29	4 ml
BA R-6651	CONTROL 1	light green	Refer to	QC-Rep	ort for ex	pected va	lue and		4 ml
BA R-6652	CONTROL 2	dark red	accepta	ble range	91				4 ml
Conversion: Adrenaline (ng/ml) x 5.46 = Adrenaline (nmol/l) Noradrenaline (ng/ml) x 5.91 = Noradrenaline (nmol/l) Dopamine (ng/ml) x 6.53 = Dopamine (nmol/l)									

Content: Acidic buffer with non-mercury stabilizer, spiked with defined quantity of adrenaline,

noradrenaline, and dopamine

 \triangle *for the determination of dopamine in plasma the additional **Standard A/B** is mandatory!

4.2 Additional materials and equipment required but not provided in the kit

- Calibrated precision pipettes to dispense volumes between 10 1000 μl
- Polystyrene tubes and suitable rack
- Temperature controlled water bath, heating block or incubator (37 $^{\circ}$ C)
- Centrifuge capable of at least 3,000 x g
- Suitable device for aspirating or decanting
- Shaker (shaking amplitude 3 mm; approx. 600 rpm)
- Gamma counter;
- Vortex mixer
- Absorbent material (paper towel)
- Water (deionized, distilled or ultra-pure)

5. <u>Sample collection and storage</u>

Plasma

Whole blood should be collected by venipuncture into centrifuge tubes containing EDTA as anti-coagulant (e.g. MonovetteTM or VacuetteTM for plasma) and centrifuged at room temperature immediately after collection.

Haemolytic and especially lipemic samples should not be used for the assay.

Storage: up to 6 hours at 2 - 8 °C, for longer period (up to 6 month) at -20 °C. Repeated freezing and thawing should be avoided.

Urine

Spontaneous urine or 24-hour urine, collected in a bottle containing 10 - 15 ml of 6 M HCl, can be used. *If 24-hour urine is used please record the total volume of the collected urine.* If the percentage of the final concentration of acid is too high, the buffer capacity of the Extraction Buffer is insufficient. As a consequence catecholamines will not be extracted adequately.

Storage: up to 48 hours at 2 - 8 °C, up to 24 hours at room temperature, for longer periods (up to 6 month) at -20 °C. Repeated freezing and thawing should be avoided. Avoid exposure to direct sunlight.

6. <u>Test procedure</u>

Allow all reagents – with the exception of Precipitating Reagent - to reach room temperature and mix thoroughly by gentle inversion before use. Number the assay tubes accordingly. Duplicates are recommended.

 \triangle Pipetted liquids should not adhere to the wall of the RIA tubes. If necessary please centrifuge the tubes for 1 minute at 500 x g to spin down adhering liquids.

6.1 Preparation of reagents

Enzyme Solution

Reconstitute the content of the vial labelled 'Enzyme' with 1 ml water (deionized, distilled or ultra-pure) and mix thoroughly. Add 0.3 ml of Coenzyme followed by 0.7 ml of Adjustment Buffer. The total volume of the Enzyme Solution is 2.0 ml.

The Enzyme Solution has to be prepared freshly prior to the assay (not longer than 10 - 15 minutes in advance). Discard after use!

6.2 Sample preparation, extraction and acylation

 \triangle *for the determination of **dopamine in plasma** the additional **Standard A/B** is mandatory!

- 1. Pipette 10 μl of standards and controls, 10 μl of urine samples and 300 μl of plasma samples into the respective wells of the Extraction Plate.
- 2. Add 250 µl of water (deionized, distilled, or ultra-pure) to the wells with standards, controls and urine samples.
- 3. Pipette 50 µl of Assay Buffer into all wells.
- 4. Pipette 50 µl of Extraction Buffer into all wells.
- 5. Cover the plate with Adhesive Foil. Incubate for 30 min at RT (20 25 °C) on a shaker (approx. 600 rpm).
- **6.** Remove the foil and empty the plate. Blot dry by tapping the inverted plate on absorbent material.
- Pipette 1 ml water (deionized, distilled, or ultra-pure) into all wells. Incubate the plate for 5 min at RT (20 25 °C) on a shaker (approx. 600 rpm). Empty plate and blot dry by tapping the inverted plate on absorbent material.
- **8.** Pipette **150 µl** of **Acylation Buffer** into all wells.
- 9. Pipette 25 µl of Acylation Reagent into all wells.
- **10.** Incubate **15 min** at **RT** (20 25 °C) on a **shaker** (approx. 600 rpm).
- **11.** Empty the plate. Blot dry by tapping the inverted plate on absorbent material.
- 12. Pipette 1 ml water (deionized, distilled, or ultra-pure) into all wells. Incubate the plate for 5 min at RT (20 25 °C) on a shaker (approx. 600 rpm). Empty plate and blot dry by tapping the inverted plate on absorbent material.
- **13.** Pipette **150** µl of **Hydrochloric Acid** into all wells.
- **14.** Cover plate with adhesive foil. Incubate **10 min** at **RT** (20 25 °C) on a **shaker** (approx. 600 rpm). Remove the foil.

100 µl

△ Do not decant the supernatant thereafter!

The following volumes of the supernatant are needed for the subsequent RIA:

Adrenaline

Noradrenaline

20 µl

Dopamine (standards + urine) 10 μl

Dopamine (plasma)

25 µl

6.3 Adrenaline RIA

- 1. Pipette 100 µl of Hydrochloric Acid into the tubes for the NSB.
- 2. Pipette 100 µl of the extracted standards, controls and samples into the respective tubes.
- **3.** Pipette **25** µl of **Enzyme Solution** (refer to 6.1) into all tubes (except totals).
- 4. Mix thoroughly and incubate for 30 min at 37 °C.
- 5. Pipette 50 µl of the ¹²⁵I Adrenaline into all tubes.
- **6.** Pipette **50 μl** of **Adrenaline Antiserum** into **all tubes** *(except totals and NSB)*; mix thoroughly.
- 7. Cover tubes. Incubate for 15 20 h (overnight) at 2 8 °C.

Alternatively incubate for 2 h at RT (20 - 25 °C) on a shaker (approx. 600 rpm).

- Mix the chilled (2 8 °C) Precipitating Reagent thoroughly, pipette each 500 μl into all tubes (except totals), and mix on a vortex.
- 9. Incubate for 15 min at 2 8 °C.

10. Centrifuge for **15 min** at **3,000 x g**, if possible in a refrigerated centrifuge.

- **11. Decant** or aspirate the **supernatant** carefully *(except totals)*. Blot the tubes dry and leave them upside down for 2 minutes.
- **12. Count** all tubes for **1 min** in a gamma counter.

6.4 Noradrenaline RIA

- 1. Pipette 20 µl of Hydrochloric Acid into the tubes for the NSB. 2. Pipette 20 µl of the extracted standards, controls and samples into the respective tubes. 3. Pipette 25 µl of Enzyme Solution (refer to 6.1) into all tubes (except totals). 4. Mix thoroughly and incubate for 30 min at 37 °C. 5. Pipette 50 µl of the ¹²⁵I Noradrenaline into all tubes. 6. Pipette 50 µl of Noradrenaline Antiserum into all tubes (except totals and NSB); mix thoroughly. 7. Cover tubes. Incubate for 15 - 20 h (overnight) at 2 - 8 °C. Alternatively incubate for 2 h at RT (20 - 25 °C) on a shaker (approx. 600 rpm). 8. Mix the chilled (2 - 8 °C) Precipitating Reagent thoroughly, pipette each 500 µl into all tubes (except totals), and mix on a vortex. 9. Incubate for 15 min at 2 - 8 °C. **10.** Centrifuge for **15 min** at **3,000 x g**, if possible in a refrigerated centrifuge. 11. Decant or aspirate the supernatant carefully (except totals). Blot the tubes dry and leave them upside down for 2 minutes. 12. Count all tubes for 1 min in a gamma counter. 6.5 **Dopamine RIA** $/ \mathbb{N}$ *for the determination of dopamine in plasma the additional **Standard A/B** is mandatory! 1. Pipette 10 µl of Hydrochloric Acid into the tubes for the NSB. 2. Pipette 10 µl of the extracted standards, 10 µl of the extracted controls, 10 µl of the extracted urine samples and 25 µl of the extracted plasma samples into the respective tubes. 3. Pipette 25 µl of Enzyme Solution (refer to 6.1) into all tubes (except totals). 4. Mix thoroughly and incubate for 30 min at 37 °C. 5. Pipette 50 µl of the ¹²⁵I Dopamine into all tubes. 6. Pipette 50 µl of Dopamine Antiserum into all tubes (except totals and NSB); mix thoroughly. 7. Cover tubes. Incubate for 15 - 20 h (overnight) at 2 - 8 °C. Alternatively incubate for 2 h at RT (20 - 25 °C) on a shaker (approx. 600 rpm). 8. Mix the chilled (2 - 8 °C) Precipitating Reagent thoroughly, pipette each 500 µl into all tubes (except totals), and mix on a vortex. 9. Incubate for 15 min at 2 - 8 °C. 10. Centrifuge for 15 min at 3,000 x g, if possible in a refrigerated centrifuge. 11. Decant or aspirate the supernatant carefully (except totals). Blot the tubes dry and leave them upside down for 2 minutes.
 - 12. Count all tubes for 1 min in a gamma counter.

7. **Calculation of results**

		Adrenaline	Noradrenaline	Dopamine
Measuring range	Urine	0.5 - 200 ng/ml	1.4 - 1 000 ng/ml	3.8 – 2 000 ng/ml
	Plasma	24 – 6 667 pg/ml	54 – 33 333 pg/ml	39 – 26 667 pg/ml

Subtract the mean cpm of the non-specific binding NSB from the mean cpm of standards, controls and samples.

The standard curve from which the concentrations in the samples can be read off, is obtained by plotting the percentage of (B-NSB)/ (B₀-NSB) measured for the standards (linear, y-axis) against the corresponding standard concentrations (logarithmic, x-axis).

Use a non-linear regression for curve fitting (e.g. spline, 4- parameter, akima).

This assay is a competitive assay. This means: the counts are decreasing with increasing concentrations of the analyte. Counts found below the standard curve correspond to high concentrations of the analyte in the sample and have to be reported as being positive.

Urine samples and controls

The concentrations of the urine samples and the Controls 1 & 2 can be read directly from the standard curve.

Calculate the 24 h excretion for each urine sample: $\mu g/24h = \mu g/I \times I/24h$

Plasma samples

Adrenaline and Noradrenaline: The read concentrations of the **plasma samples** have to be **divided by 30.** Dopamine: The read concentrations of the **plasma samples** have to be **divided by 75.**

Conversion

Adrenaline (ng/ml) x 5.46 = Adrenaline (nmol/l) Noradrenaline (ng/ml) x 5.91 = Noradrenaline (nmol/l) Dopamine (ng/ml) x 6.53 = Dopamine (nmol/l)

Expected reference values

It is strongly recommended that each laboratory should determine its own reference values.


	Adrenaline	Noradrenaline	Dopamine
24-hour urine	< 20 µg/day	< 90 µg/day	< 600 µg/day
	(110 nmol/day)	(535 nmol/day)	(3 900 nmol/day)
Plasma	< 100 pg/ml	< 600 pg/ml	< 100 pg/ml

7.1 Quality control

It is recommended to use control samples according to national regulations. Use controls at both normal and pathological levels. The kit controls or other commercial controls should fall within established confidence limits. The confidence limits of the kit controls are printed on the QC-Report.

7.2 Typical standard curves

Examples, do not use for calculation!



8. Assay characteristics

Analytical Sensitivity		Adrenaline	Noradrenaline	Dopamine	
(Limit of Detection)	Urine	0.5 ng/ml	1.4 ng/ml	3.8 ng/ml	
	Plasma	24 pg/ml	54 pg/ml	39 pg/ml	

	Substance	Cros	Cross Reactivity (%)			
		Adrenaline	Noradrenaline	Dopamine		
	Derivatized Adrenaline	100	0.08	0.02		
Analytical Specificity	Derivatized Noradrenaline	0.13	100	6.4		
(Cross Reactivity)	Derivatized Dopamine	< 0.01	0.03	100		
	Metanephrine	0.18	< 0.01	< 0.01		
	Normetanephrine	< 0.01	0.16	0.01		
	3-Methoxytyramine	< 0.01	< 0.01	0.49		
	3-Methoxy-4-hydroxyphenylglycol	< 0.01	< 0.01	< 0.01		
	Tyramine	< 0.0007	< 0.01	0.18		
	Phenylalanine, Caffeinic acid, L- Dopa, Homovanillic acid, Tyrosine, 3-Methoxy-4-hydroxymandelic acid	< 0.01	< 0.01	< 0.01		

Precision							
Intra-Assay U	rine (n =	40)		Intra-Assay P	lasma (n	= 40)	
	Sample	Range (ng/ml)	CV (%)		Sample	Range (ng/ml)	CV (%)
	1	15.8 ± 1.1	7.0		1	146 ± 17.4	12.0
Adrenaline	2	22.3 ± 1.7	7.4	Adrenaline	2	389 ± 38.7	10.1
	3	45.2 ± 5.1	11.3		3	1 271 ± 88.4	7.0
	1	86.8 ± 6.8	7.8		1	992 ± 85.8	9.3
Noradrenaline	2	122 ± 10.9	8.9	Noradrenaline	2	1 811 ± 224	12.3
	3	244 ± 21.9	8.9		3	4 935 ± 663	13.4
	1	283 ± 44.3	16.1		1	346 ± 30.8	8.8
Dopamine	2	338 ± 54.7	15.9	Dopamine	2	880 ± 111	12.3
	3	594 ± 170	28.7		3	2 588 ± 742	24.0
Inter-Assay U	rine (n =	18)		Inter-Assay Plasma (n = 20)			
	Sample	Range (ng/ml)	CV (%)		Sample	Range (ng/ml)	CV (%)
	1	15.5 ± 1.5	9.5		1	129 ± 12.7	9.8
Adrenaline	2	21.0 ± 2.5	11.7	Adrenaline	2	347 ± 31.9	9.2
	3	42.7 ± 5.0	11.7		3	1 139 ± 128	11.3
	1	77.7 ± 8.5	10.9		1	754 ± 184	24.4
Noradrenaline	2	104 ± 9.4	9.1	Noradrenaline	2	1 661 ± 176	10.9
	3	198 ± 22.7	11.5		3	4 049 ± 391	9.7
	1	225 ± 34.7	15.4		1	260 ± 74.7	28.8
Dopamine	2	272 ± 55.8	20.5	Dopamine	2	761 ± 173	22.7
	3	452 ± 118	26.0		3	2 216 ± 564	25.5

			Serial dilution up to	Range (%)	Mean (%)
		Urine	1:128	99 - 114	105
	Adrenaline	Plasma	1:128	107 - 113	110
Linearity		Urine	1:128	93 - 106	98
	Noradrenaline	Plasma	1:128	95 - 113	103
		Urine	1:128	90 - 121	105
	Dopamine	Plasma	1:128	67 - 90	83

			Concentration range	Range (%)	Mean (%)
		Urine	5.2 – 48.8 ng/ml	101 - 111	105
	Adrenaline	Plasma	25.3 – 1 001 pg/ml	105 - 119	111
Recovery		Urine	62.9 – 292 ng/ml	99 - 107	102
	Noradrenaline	Plasma	377 – 4 457 pg/ml	80 - 101	92
		Urine	137 – 1 823 ng/ml	79 - 126	110
	Dopamine	Plasma	20.3 – 5 158 pg/ml	74 - 94	85

		Urine	HPLC = 0.95 RIA - 0.03	r = 0.99; n = 21		
Method Comparison versus HPLC*	Adrenaline	Plasma	HPLC = 0.80 RIA - 0.03	r = 0.96; n = 20		
		Urine	HPLC = 1.23 RIA - 0.12	r = 0.99; n = 21		
	Noradrenaline	Plasma	HPLC = 1.27 RIA - 0.14	r = 0.99; n = 20		
		Urine	HPLC = 1.07 RIA + 0.01	r = 0.98; n = 21		
	Dopamine	Plasma	HPLC = 1.00 RIA + 0.003	r = 0.96; n = 20		
*The concentrations were accessed using both the DIA and the HDLC method (external OC camples						

*The concentrations were assessed using both the RIA and the HPLC method (external QC samples from UK NEQAS). The correlation between RIA and HPLC is excellent. This means, that the RIA measure equally good when compared to the UK NEQAS HPLC data. Please take in mind, that the UK control values are the mean of about 40 different HPLC users, and contain always one pathological sample per sending.

9. <u>References/Literature</u>

- (1) Kvetnansky et al. Stress Stimulates Production of Catecholamines in Rat Adipocytes. Cellular and Molecular Neurobiology, 32(5):801-813 (2012)
- (2) Wetsch et al. Preoperative stress and anxiety in day-care patients and inpatients undergoing fast-track surgery. British Journal of Anaesthesia, 103 (2):199–205 (2009)
- (3) Mahapatra et al. The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters. Journal of Hypertension, 24(5):895-904 (2006)

For orders, please contact:

Immuno-Biological Laboratories, Inc. (IBL-America) 8201 Central Ave NE, Suite P Minneapolis, MN 55432 Email: info@ibl-america.com Web: www.ibl-america.com Phone: (888) 523-1246 Fax: (763) 780-2988

\triangle For updated literature or any other information please contact your local supplier.

Symbols:

+2, *B	Storage temperature	***	Manufacturer	Σ	Contains sufficient for <n> tests</n>
\sum	Expiry date	LOT	Batch code	I V D	For in-vitro diagnostic use only!
i	Consult instructions for use	CONT	Content	CE	CE labelled
Λ	Caution	REF	Catalogue number	RUO	For research use only!